Trial results for the RECOVER-NEURO study, investigating interventions for cognitive dysfunction in Long COVID patients, were posted on ClinicalTrials.gov on 2025-07-18, detailing enrollment counts for its various arms, with a total of 328 participants.
Background
Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), encompasses a wide range of persistent symptoms that can last for weeks, months, or even years after the initial COVID-19 infection. Among the most debilitating of these symptoms is cognitive dysfunction, often referred to as “brain fog.” This can manifest as issues with memory, attention, executive function, and information processing, significantly impacting daily life and quality of life for affected individuals. The RECOVER-NEURO platform protocol aims to evaluate potential interventions to address this specific and widespread challenge within the Long COVID patient population.
Trial design
This completed study, identified as Phase NA, enrolled 328 participants with Long COVID, Long COVID-19, or Long COVID19. The RECOVER-NEURO trial is a prospective, multi-center, multi-arm, randomized, controlled platform trial designed to evaluate various interventions for PASC-mediated cognitive dysfunction. The protocol is structured to be flexible, allowing for integration into diverse healthcare, remote, and community settings. The core hypothesis is that PASC-associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on these areas. The trial did not list specific primary outcome measures in the posted results.
Key results
The posted results detail the total number of participants enrolled in each appendix (intervention arm) for the RECOVER-NEURO study:
- Participants enrolled in the BrainHQ Active Comparator group: 64
- Participants enrolled in the BrainHQ group: 67
- Participants enrolled in the BrainHQ + PASC CoRE group: 66
- Participants enrolled in the Brain HQ + tDCS-active group: 66
- Participants enrolled in the Brain HQ + tDCS-sham group: 65
What this means
The posting of these results indicates the completion of participant enrollment across various intervention arms within the RECOVER-NEURO platform trial. The detailed enrollment counts show the distribution of the 328 participants across different approaches aimed at addressing cognitive dysfunction in Long COVID. While these results do not provide efficacy data, they confirm the operational progress of this multi-arm study, demonstrating the successful recruitment and allocation of participants to investigate potential treatments for a critical aspect of Long COVID.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05965752, titled "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms", were posted on 2025-07-18 on clinicaltrials.gov.